Drugmakers Pfizer and BioNTech announced Monday that the results of the latest clinical trials of their covid-19 vaccine for children aged 5 to 11 years have generated a “robust” antibody response and are safe, bringing the possibility of a children’s serum available by the end of October closer.
The tests were conducted on 2,268 participants between 5 and 11 years of age with inoculation of two doses of the vaccine, with a three-week period between each dose.
The doses used are 10 micrograms, instead of the 30 micrograms used in the vaccines for those over 12 years of age.
According to the company, the vaccine offered “a strong response in this group of children after the second dose” and “was also well tolerated, with side effects comparable” to those of older people.
“We look forward to extending the protection afforded by the vaccine to the younger population, subject to regulatory clearance, especially now as we monitor the spread of the delta variant and the substantial threat it poses to children,” Albert Bourla, president of Pfizer, said in a statement.
The Pfizer/BioNTech vaccine is formally approved in the United States by authorities for those 16 years of age and older, and has emergency authorization for people aged 12 to 15 years.
If the prior vaccine review process is completed, the vaccine for children aged 5 to 11 years could be available by the end of October.